Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 1Pancreatic Neoplasms 1Nephrotic Syndrome 1Neoplasm Metastasis 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Colorectal Adenocarcinoma 1Cholangiocarcinoma 1BRAF V600 Colorectal Cancer 1Arthritis, Rheumatoid 1Amyloidosis 1Adenomatous Polyposis Coli 1

Interventions

Cisplatin 161Fluorouracil 135Paclitaxel 127Radiotherapy 125Oxaliplatin 88Carboplatin 72Docetaxel 71Irinotecan 60pembrolizumab 57Leucovorin 57Capecitabine 57Radiation 48Esophagectomy 44Surgical Procedures, Operative 41Drug Therapy 38Neoadjuvant Therapy 28Cetuximab 25Nivolumab 24Bevacizumab 21camrelizumab 20Trastuzumab 20S 1 (combination) 19Chemoradiotherapy 19Magnetic Resonance Spectroscopy 18Epirubicin 16Albumin-Bound Paclitaxel 16Blood Specimen Collection 15tislelizumab 14Taxes 14Radiotherapy, Intensity-Modulated 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Pharmaceutical Preparations × Gastrointestinal × Clear all
NCT00318903 2023-05-25

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

University of Alabama at Birmingham

Phase 2 Completed
25 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡